A new study published in Neurology suggests that estradiol-based hormone therapy may offer cognitive benefits for postmenopausal women, specifically in areas of memory function. According to the research, postmenopausal women who used estradiol – whether in oral or transdermal form – scored higher on specific memory measures compared to their peers who never used menopausal hormone therapy (MHT).
The findings add nuance to the ongoing discussion surrounding hormone therapy, its potential risks, and its benefits for women beyond symptom relief in menopause. While hormone replacement therapy has historically been prescribed to help manage hot flashes, night sweats, and bone health, its role in cognitive outcomes has been more controversial. This new research provides evidence that certain types of hormone therapy, particularly estradiol-based formulations, may play a protective role for memory in healthy aging women.
The Study at a Glance
The research, reported by MedPage Today (August 27, 2025), evaluated memory and executive function in a cohort of cognitively normal postmenopausal women. Participants were divided into groups based on their history of hormone therapy use, specifically looking at those who had never used MHT, those who used oral estradiol, and those who used transdermal estradiol.
The investigators focused on three primary domains of cognition:
- Episodic memory (the ability to recall specific past events)
- Prospective memory (the ability to remember to perform future tasks or intentions)
- Executive function (skills related to planning, problem-solving, and multitasking)
Key Findings:
- Transdermal estradiol use was linked to better episodic memory scores.
- Oral estradiol use was associated with higher prospective memory scores.
- Executive function scores were not significantly impacted by either oral or transdermal estradiol.
- Earlier age at menopause correlated with lower scores across all three domains, underscoring the role of ovarian hormones in supporting cognition.
These findings suggest that estradiol-based therapies may influence specific memory systems differently depending on the formulation and delivery method.
Why Memory Matters in Menopause
Menopause, which typically occurs between ages 45 and 55, is marked by a decline in ovarian hormone production, including estradiol – the most potent and biologically active form of estrogen. Many women report subjective memory complaints during this time, often referred to as “brain fog” or difficulties with concentration and recall.
Scientific research has long suggested that estradiol influences brain regions critical for memory, such as the hippocampus and prefrontal cortex. Animal studies have shown that estradiol enhances synaptic plasticity, increases dendritic spine density, and improves neural signaling in these areas. In humans, neuroimaging studies have demonstrated that estrogen may help maintain connectivity in memory-related networks.
The present findings support the hypothesis that estradiol replacement could bolster memory performance in postmenopausal women, even in those who are otherwise cognitively normal.
Timing and Formulation: Why They Matter
One of the most important aspects of the study is the distinction between oral and transdermal estradiol.
- Transdermal estradiol, delivered through patches, bypasses the liver and provides more stable blood levels of hormone. This route was associated with stronger episodic memory performance – the ability to recall past experiences in detail. Episodic memory is particularly vulnerable in aging and in conditions such as Alzheimer’s disease, so this finding is noteworthy.
- Oral estradiol, taken in pill form, undergoes first-pass metabolism in the liver, potentially leading to different patterns of hormone distribution in the body and brain. In this study, it was linked to better prospective memory, which governs remembering tasks such as taking medication on time or keeping appointments.
The study also highlights that the age of menopause onset plays a critical role in cognitive outcomes. Women who experience earlier menopause, whether naturally or due to surgery (such as oophorectomy), tended to have lower scores across memory and executive domains. This supports the “critical window hypothesis,” which suggests that earlier loss of estrogen may accelerate cognitive decline, while timely hormone therapy might help preserve function.
What About Executive Function?
Interestingly, the researchers found no association between estradiol use and executive function. Executive skills involve high-level cognitive processes such as working memory, flexible thinking, and decision-making. While estradiol may enhance memory-related networks, its influence on executive systems is less clear. It’s possible that executive function relies more heavily on other neural circuits or that hormone therapy alone is insufficient to preserve these skills.
Future research will be needed to clarify whether longer treatment duration, different dosages, or combination therapies (such as estradiol plus progestin) have stronger effects on executive performance.
Clinical Implications
These results have several implications for clinical practice and for women considering hormone therapy:
- Personalized decisions matter. Not all hormone therapies are equal. Estradiol appears to offer specific cognitive benefits that may not be seen with conjugated equine estrogens (CEE), which were the primary formulation studied in the large Women’s Health Initiative (WHI).
- Delivery route influences outcomes. Women and clinicians should weigh the potential differences between oral and transdermal estradiol, especially if cognitive outcomes are a consideration.
- Timing may be critical. The benefits of hormone therapy could be more pronounced when initiated closer to menopause onset, before significant estrogen deficiency impacts the brain.
- Memory support as an added benefit. While hormone therapy should not be prescribed solely for cognitive protection at this stage, the potential memory benefits may provide an additional factor in shared decision-making for symptom management.
Limitations of the Study
As with any observational study, several limitations must be considered:
- Causality cannot be established. While associations were found, the study does not prove that estradiol directly improves memory. Other factors, such as socioeconomic status, education level, or lifestyle, may play a role.
- Population studied. The women included were cognitively normal at baseline. Results may not apply to those with mild cognitive impairment or dementia.
- Duration and dosage not specified. The study did not provide detailed comparisons of hormone dose, treatment length, or whether women used continuous versus cyclic regimens.
- Long-term safety considerations. While estradiol may aid memory, hormone therapy carries known risks, including increased risks of thromboembolism, stroke, and breast cancer in certain populations.
The Bigger Picture
This study contributes to a growing body of evidence that estrogen plays a vital role in women’s brain health. With women living a third of their lives in a postmenopausal state, understanding how to best protect cognitive function is becoming increasingly important.
While hormone therapy remains a complex decision requiring individualized risk-benefit analysis, the evidence suggests that estradiol-based regimens may help preserve certain aspects of memory. More randomized controlled trials are needed to confirm these findings, determine the most effective formulations and doses, and explore whether these memory benefits translate into lower risks of dementia in the long term.
Conclusion
The new Neurology study highlights that estradiol-based hormone therapy is associated with higher memory scores in cognitively normal postmenopausal women, with transdermal formulations linked to better episodic memory and oral formulations associated with better prospective memory. Though no effect was observed on executive function, the findings underscore the importance of estrogen in maintaining cognitive health after menopause.
For women and clinicians, this research provides fresh insight into how hormone therapy might not only alleviate menopausal symptoms but also support brain health. As science continues to uncover the nuanced effects of estrogen on cognition, hormone therapy may one day be seen not just as a treatment for hot flashes and bone loss, but as a potential ally in protecting memory during healthy aging.
El Camino Women’s Medical Group offers the latest Minimally Invasive Solutions for gynecologic problems. Drs. Amy Teng, Erika Balassiano, Pooja Gupta, and Vivian Wan, all members of AAGL (American Association of Gynecologic Laparoscopy), are highly trained and experienced in the field of Minimally Invasive Gynecologic Surgery. Dr. Erika Balassiano has also completed a Minimally Invasive Gynecologic Surgery Fellowship under the supervision of world-renowned Dr. Camran Nezhat. Angel Wong, PA-C, is a physician assistant who sees patients for routine and lower-acuity care.
All of our physicians are El Camino Hospital doctors and operate and deliver at the Mountain View campus.
As part of El Camino Women’s Medical Group’s commitment to comprehensive care for women, we offer in-network mental health services with world-renowned psychiatrist Dr. Rania Awaad and experienced therapist Daniya Ahmed, LMFT. For women seeking to improve their health through a healthier diet, Mariam AlAgha, MS, is an excellent nutritionist with over a decade of success helping women achieve their health goals. Her services are also in network.
Serving Mountain View, Los Altos, Los Altos Hills, Atherton, Palo Alto, Redwood City, Burlingame, Saratoga, Cupertino, Sunnyvale, Los Gatos, Campbell, San Jose, Santa Clara, Silicon Valley, Milpitas, Fremont, South Bay, East Bay, and North Bay.